News By Tag * Contract Pharma * Pharmaceutical Organisations * Low Cost Contract Manufacturing * Contract Pharma Development * More Tags... Industry News News By Location Country(s) Industry News
|  Pharmaceuticals Contract Pharma 2008-2023Visiongain is proud to announce the release of the brand new report "Contract Pharma 2008-2023".The revenue for world contract manufacturing business in 2007 was approximately $30bn, with a growth rate of 6% from 2006.
By: Visiongain Ltd. The revenue for world contract manufacturing business in 2007 was approximately $30bn, with a growth rate of 6% from 2006. The technical expertise and cost savings offered by contract manufacturing organisations (CMOs) make them increasingly essential to you and your organisation. Greater emphasis has been put on European CMOs to leverage low-cost contract manufacturing markets, such as those existing in India and China, to enhance cost efficiency. Many CMOs in Europe have turned to biotech services as a means of avoiding competition with lower-cost API companies based in developing countries. In common with European service providers, North American CMOs are adopting a dynamic approach. Also, they are providing other services, such as packaging, logistics and marketing support. Are you taking advantage of the opportunities available? This unique report will guide you and inform you on how to benefit from the options - you should take the opportunity today. Recent years have seen the emergence of moderate level competition from Indian and Chinese CMOs. This new visiongain report - Contract Pharma 2008-2023 - evaluates the prospects for outsourcing manufacturing and other operations from pharmaceutical companies, especially off-shoring to developing nations such as China and India. Furthermore, this report analyses the increasing trend for Japan to outsource services abroad. In particular, the following factors have been highlighted in this report: • Synchronization of regulations • Mutual recognition of GMP documentation • Improved information exchange. Why you should buy this report: In Contract Pharma 2008-2023 you will receive the following essential information for understanding the contract pharma market: - The value of the contract pharma business market and its principal market segments from 2008 to 2023, with detailed forecasts and growth analyses - Market drivers and restraints, including a comprehensive SWOT analysis - Comprehensive views of key opinion leaders on contract pharma, including leading companies, with full interview transcripts from our in-depth survey worldwide - The companies involved in contract pharma business and their business strategy - The present state of contract pharma business and future trends there - What contract pharma opportunities exist for market entrants, both established companies and newcomers - The main concerns for outsourcing clinical trials to CROs - Changes in contract pharma regulations - CMOs are increasingly undertaking analytical testing and other value-added services alongside traditional contract manufacturing of APIs. In some major CMOs, these value-added services have taken up significant proportion of their revenue generation. This rate will increase further in the coming decade. The establishment of large, global companies offering a full range of contract services has led to a change in the image of CROs and CMOs. There has been a shift in the business model of CMOs to integrate themselves more fully into the supply chain of pharmaceutical and biopharmaceutical companies by offering a wider range of services. The report is intended for the following professionals, amongst others: - Directors, business development managers and researchers of pharmaceutical and biopharmaceutical companies worldwide - Directors, business development managers and researchers in the healthcare industry - Policy makers, researchers, analysts and academic researchers Companies Listed Actavis Advanced Medical Optics Altana Anhui BBCA Biochemical AstraZeneca Avecia Aurobindo Baxter International BEBAC - Consultancy Services Bristol-Myers- Cadila Healthcare Carbogen and Amcis Cellerix Celltrion Chembiotek Clininvent Research Cognizant Manipal Acunova Damon Biotech Dishman Divi's Labs Dr. Reddy's Laboratories Ranbaxy Eli Lilly GlaxoSmithKline Granules India HCL Systems iGATE Clinical Research International Johnson & Johnson Jubilant Organosys Matrix Matrix Strides Merck Mylan Natco Neuland Neeman Medical International Nicholas Piramal Northeast Gen Pharma Factory Novartis Novo Nordisk Orchid Chemicals and Pharma Patheon Pfizer Progenitor International Research Quintiles Ranbaxy Rhodia Roche Sandoz Sanofi-Aventis (Aventis) Shadong XINHUA Pharm Shasun SIRO Clinpharm Solvay Suven Life Sciences Veeda Clinical Research Wyeth Zhejiang Medicine Zhejiang NHU Zhejiang Chiral Zyday Cadila Visiongain ltd. 4th Floor, BSG House, 226-236 City Road, London EC1V 2QY United Kingdom Telephone: +44 (0) 20 7336 6100 Fax: +44 (0) 20 7549 9930 info@visiongainglobal.com Or Visit at: http://www.visiongain.com/ Or http://www.visiongain.com # # # Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services. End
| ||||||||||||||||||||||||||||||||||||||||||||
